Once-monthly Cariprazine Depot clears first clinical safety test as Mapi targets 2029 NDA
Cariprazine Depot clears its first clinical safety hurdle as Mapi targets a U.S. IND in 2026 and potential 2029 NDA. See what comes next.
Pharma & Biotech
Pharma & Biotech
RiboX RXIM002 FDA clearance takes circular RNA in vivo CAR-T into autoimmune disease trials
RiboX Therapeutics has received clearance from the United States Food and Drug Administration to begin clinical testing of RXIM002, an experimental treatment designed to create temporary anti-CD19 CAR-T cells directly inside the body of a patient with autoimmune disease. The August 8, 2026 investigational new drug clearance allows RiboX Therapeutics to initiate the Phase 1
Pharma & Biotech
Genmab and AbbVie clarify EPCORE DLBCL-1 missed sole US overall survival endpoint
Genmab and AbbVie clarify that EPCORE DLBCL-1 missed its sole US overall survival endpoint despite a PFS benefit for epcoritamab.
Pharma & Biotech
FDA expands Skyrizi to children as AbbVie introduces weight-based 55 mg dose
AbbVie has secured a broad pediatric label for Skyrizi, adding both plaque psoriasis and active psoriatic arthritis alongside a new dose for children weighing less than 40 kg. The approval could strengthen treatment choice, although the evidence supporting the two indications is not equally direct.
Pharma & Biotech
AbbVie nears reported $10.9bn Apogee deal as zumilokibart heads toward Phase 3
AbbVie could pay a substantial premium for Apogee Therapeutics and its long-acting eczema antibody, but the reported deal depends on Phase 3 success and differentiation from established immunology drugs.
Pharma & Biotech
AbbVie’s Venclexta update puts long-term CLL treatment-free survival back in focus
Find out how AbbVie’s nine-year venetoclax CLL data could reshape fixed-duration treatment decisions and long-term leukemia care.
Pharma & Biotech
How AbbVie’s DECNUPAZ approval changes the treatment conversation in aggressive BPDCN
Find out how AbbVie’s DECNUPAZ approval could change BPDCN treatment while raising new safety and adoption questions.
Pharma & Biotech
Can AbbVie’s Juvéderm strategy turn subtle aesthetics into the next growth engine for fillers
AbbVie is repositioning Juvéderm for the “undetectable” aesthetics era. Read what this means for injectables, clinicians, and market competition.
Pharma & Biotech
AbbVie’s AFFIRM trial: what clinicians should watch next for risankizumab in Crohn’s disease
AbbVie reports positive Phase 3 AFFIRM trial results for risankizumab subcutaneous induction in Crohn’s disease. Discover what the findings mean for treatment.
Pharma & Biotech
How AbbVie’s epcoritamab reshapes the competitive calculus in relapsed diffuse large B-cell lymphoma
AbbVie’s Phase 3 epcoritamab data raise critical questions about survival endpoints and bispecific antibodies in relapsed lymphoma. Read the full analysis.